Genzyme and Bayer enter into a decisive licensing tie-up in a deal valued at US$ 2.9 B in the areas of cancer and multiple sclerosis. Under the agreement, Bayer transfers the worldwide development and distribution rights for Campath® for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and exclusive worldwide licenses for Leukine® (sargramostim) and Fludara® (fludarabine phosphate) for all present and future indications.